Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today provided an update to its shareholders on the utilization of its Equity Line of Credit (“ELOC”) and At-the-Market (“ATM”) facility, as well as its outstanding number of shares.

Equity Issuance Update as of End of Day November 7, 2024:

• Total number of shares traded since ELOC and ATM Activation: 153,085,471
• Total number of shares sold via ELOC and ATM: 11,920,744, representing approximately 8% of total traded shares since the ELOC and ATM initiation
• Total Outstanding Shares: 12,059,043

In addition, Aditxt announces that its use of the Shelf registration statement, inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024. This suspension will remain in effect at least until Aditxt, Appili Therapeutics, Inc., and Evofem Biosciences, Inc. complete their respective quarterly filings, and Aditxt has filed updated pro-forma financial statements with respect to such proposed acquisitions.

Aditxt is also actively pursuing debt as the primary method of financing to meet the capital requirements for its acquisition strategy, thereby minimizing reliance on equity-based financing. By prioritizing debt, Aditxt intends to limit dilution and continue delivering value to shareholders while positioning the company for growth.

Aditxt remains committed to transparent communication regarding its capital structure and financing strategy to keep stakeholders informed on developments impacting shareholder value.

Disclaimer

The above represents usage of the ELOC and ATM facilities to date, but is not necessarily indicative of future usage. Aditxt can provide no assurance that future usage will be consistent with its usage to date.

We cannot guarantee that future financing will be available in sufficient amounts, or on terms acceptable to us, if at all. The terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities may dilute our existing stockholders. The incurrence of indebtedness would result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights, and other operating restrictions that could adversely impact our ability to conduct our business.